Abbvie-Header Abbvie-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Oncology Drugs in Phase II Clinical Development in NORWAY

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Ultimovacs

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NORWAY Norway

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Arab Health 2021

              Participation Not Confirmed

              Update your events

              Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology

              Contact the Supplier

              Lead Product(s): UV1,Sargramostim,Ipilimumab

              Therapeutic Area: Oncology Product Name: UV1

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 11, 2021

              Details:

              Building on these promising Phase I results, Ultimovacs is currently enrolling INITIUM, its Phase II clinical trial evaluating UV1 in combination with ipilimumab and nivolumab in patients with metastatic malignant melanoma.

              PCI Biotech

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NORWAY Norway

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Arab Health 2021

              Participation Not Confirmed

              Update your events

              PCI Biotech: First US Patient Enrolled in the Fima Chem Pivotal RELEASE Study

              Contact the Supplier

              Lead Product(s): Fimaporfin,Gemcitabine,Cisplatin

              Therapeutic Area: Oncology Product Name: Amphinex

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 30, 2021

              Details:

              First US patient has been enrolled into the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients.

              Ultimovacs

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NORWAY Norway

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Arab Health 2021

              Participation Not Confirmed

              Update your events

              Ultimovacs ASA Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab

              Contact the Supplier

              Lead Product(s): UV1,GM-CSF,Pembrolizumab

              Therapeutic Area: Oncology Product Name: UV1

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 22, 2020

              Details:

              The FOCUS (First-line metastatic Or recurrent HNSCC/Checkpoint inhibitor UV1 Study) Phase II trial will evaluate the addition of UV1 to a standard of care treatment with PD-1 checkpoint inhibitor pembrolizumab as compared to pembrolizumab monotherapy.

              BerGenBio ASA

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NORWAY Norway

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Arab Health 2021

              Participation Not Confirmed

              Update your events

              BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020

              Contact the Supplier

              Lead Product(s): Bemcentinib,Cytarabine

              Therapeutic Area: Oncology Product Name: BGB 324

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 06, 2020

              Details:

              The data indicates that treatment with the bemcentinib-LDAC combination shows promising efficacy in relapsed patients who are unfit for intensive chemotherapy.